Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of ADCC-optimized antibodies for treating low-responder patients

Use of ADCC-optimized antibodies for treating low-responder patients

US Patent 7713524 · Granted May 11, 2010

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Chimeric protein in the treatment of amyloidosis2022
Markers of immune response2021
Sialylated fetuin-A as a marker of immunotherapy efficacy2021
Anti-CD303 monoclonal antibodies2020
Recombinant or transgenic factor VII composition, each factor VII molecule havin2019
Recombinant or transgenic factor VII composition, each factor VII molecule havin2019
Recombinant or transgenic factor VII composition, each factor VII molecule havin2019
Recombinant or transgenic factor VII composition, each factor VII molecule havin2019
Methods for identifying dendritic cell subsets, for determining if a patient is 2019
Pharmaceutical compositions comprising an antibody which binds the human anti-Mü2019
Biomarkers of immunotherapy efficacy2018
Monoclonal antibodies with enhanced ADCC function2018